Venture Capital Firms in Munich

AQAL Capital is a Munich-based investment firm specializing in "Integral Investing," an approach that combines rigorous financial due diligence with social, environmental, cultural, and ethical considerations. The firm focuses on state-of-the-art exponential technology companies that demonstrate potential for substantial growth and integral impact, aligning with the UN Sustainable Development Goals (SDGs) within planetary boundaries. They target seed and early-stage companies with strong leadership, proven technology, and a short runway to cash flow break-even.Founded in 2014, AQAL Capital was established by Dr. Mariana Bozesan and Thomas Schulz. Dr. Bozesan, an award-winning integral investor and serial entrepreneur, has been actively involved in venture capital and entrepreneurship since 1995. The firm's philosophy, deeply rooted in Dr. Bozesan's "Integral Investing: From Profit to Prosperity" report to the Club of Rome, aims to leverage exponentially growing technologies to address global grand challenges and foster a sustainable global society.AQAL Capital has a diverse portfolio of investments across various high-tech sectors. Notable past and current investments include CyberNet AG, one of Germany's first publicly traded internet companies; Entelios AG, a German demand response aggregator; and Penumbra, a medical device company specializing in neurovascular diseases. More recent investments include Green Spot Technologies, CrowdSmart, XO Life, Kipu Quantum, and Proxima Fusion, spanning specialty chemicals, business software, healthcare services, and alternative energy.The AQAL Capital team, led by its founders, brings extensive experience to the investment landscape, combining over 95 years of private equity and venture capital expertise, 65 years in impact investing and venture philanthropy, and 95 years of entrepreneurship know-how. Their deep sector knowledge spans exponential technology & AI, renewable energy and clean technology, medical devices, and healthcare. The team is actively involved in global initiatives, including the Club of Rome and the UN Principles for Responsible Investing (UN PRI), demonstrating a commitment to addressing global challenges through responsible venture investing.

Bavarian Capital Management is a Munich-based family office investment firm that primarily focuses on private equity and venture capital investments. The firm engages in direct investments, partnering closely with founders by offering coaching and strategic guidance to help portfolio companies achieve their goals, which may include a takeover or an IPO. While the firm initially engaged in active portfolio management encompassing listed equities, foreign exchange (FX) dealing, Contracts for Difference (CFDs), and various options strategies, its business model has evolved to almost exclusively concentrate on private equity and venture capital.The firm was founded in 2001, although its active portfolio management began in 2014. The founder, Niko Dimitrov, brings extensive experience from a distinguished career in finance. He began his journey in August 1983 at the US American investment bank Kidder Peabody & Co. in Paris, following his graduation from the European Business School and an MBA from the American University in Washington D.C. From 1985 to 1995, Dimitrov worked at Morgan Stanley in London, gaining significant experience in institutional sales and high-net-worth departments, where he also started his venture capital and private equity endeavors as a business angel.Bavarian Capital Management's diverse portfolio includes investments across various sectors. Notable companies include SILKFRED, an online platform for independent fashion brands; PAEDI PROTECT AG, specializing in skincare products for sensitive skin; MYNARIC, a developer of laser communication equipment for aerial and space networks; 4TIITOO, a pioneer in natural user experience software based on eye tracking and AI; QARMA, which utilizes proprietary algorithms to measure global market sectors; TABLECROWD, a business networking platform; INVITROCUE, a provider of bio-analytic solutions for cell-based testing and digital pathology; and SILBERTREU 24h Care.The firm's investment strategy is sector-agnostic, with a history of transactions in aerospace, e-commerce, technology, fashion, consumer goods, communication, healthcare, and food and beverage sectors. They often look to co-invest with other family offices, institutional, and individual investors. Niko Dimitrov's deep financial background and experience as a business angel underpin the firm's approach to nurturing and growing its portfolio companies.

Blue Lion is the single-family office of the entrepreneurial Schörghuber family, based in Munich, Germany. The firm serves as the central entity for the family to consolidate its financial assets, regional holdings, and investments across private equity and venture capital. Its investment philosophy centers on enhancing the "quality of life," guiding its activities to fulfill fundamental human needs such as secure living spaces, high-quality food, and opportunities for experiences and identity. The family's significant operational interests in real estate, food & beverage, and hospitality are primarily managed under the Schörghuber Group.The roots of the Schörghuber family's entrepreneurial endeavors trace back to 1954, marking a long-standing tradition of sustainable business practices. While the family's business interests have evolved over decades, Blue Lion as a dedicated family office structure manages the diversified portfolio. The firm is guided by values of being family-oriented, quality-driven, and appreciative, emphasizing diligence, discipline, and foresight in its investment approach and interactions with partners.Blue Lion's investment strategy is multifaceted, encompassing direct operational participations in businesses complementary to the Schörghuber Group's core sectors, with revenue targets between €20 million and €200 million in Europe. Its venture capital arm actively seeks opportunities in areas like Proptech, Agritech, Machine Economy, Artificial Intelligence, Fintech, Insurtech, Consumer Goods, E-Commerce, and Software Applications, investing across Seed to Later Stage companies in Europe, Switzerland, the UK, USA, and Israel. Additionally, the firm engages in fund-based investments in private equity, venture capital, and agriculture, with ticket sizes ranging from €1 million to €20 million, extending its reach to Latin America.The firm's portfolio includes direct investments in cable car operations and golf courses, as well as a leading European insurtech company. Past exits highlight a diverse investment history, including stakes in major beverage bottlers, a winery, a prefabricated house provider, and an aircraft leasing company. Beyond its investment activities, Blue Lion demonstrates a strong commitment to social responsibility through two foundations: the Josef Schörghuber-Stiftung for children in Munich, established in 1995, and the Stefan Schörghuber Stiftung, founded in 2019 by Alexandra Schörghuber and her children, which supports child and youth welfare, science, and research projects.

COFRA Holding is a diversified, family-owned enterprise that manages a global portfolio of businesses across various sectors, united by a mission to deliver lasting positive and sustainable impact. The firm operates in private equity, real estate, and asset management, alongside direct investments in retail, clean energy, and sustainable food. COFRA Holding oversees more than €35 billion in assets, combining both family capital and external client funds, and employs over 60,000 people across Europe, the Americas, and Asia.The roots of COFRA Holding trace back to 1841 when brothers Clemens and August Brenninkmeijer founded the C&A textile trading business in the Netherlands. COFRA Holding AG itself was formally established in 2001 in Zug, Switzerland, to coordinate the global business interests of the Brenninkmeijer family. The enterprise is guided by a strong ethos of ethical values, human dignity, sustainability, and social justice, aiming to be a force for good in the world while pursuing financial performance.The firm's portfolio includes several key businesses. Bregal Investments serves as COFRA's private equity arm, with various funds focusing on strategies such as European mid-market technology, US growth equity, and buyouts in the DACH region and UK mid-market. Redevco is a prominent European commercial retail and residential real estate business. Anthos Fund & Asset Management provides values-based asset management services. COFRA also makes direct investments in areas like clean energy through Sunrock Investments and sustainable food systems, including vertical farming (Intelligent Growth Solutions) and high-tech greenhouse development (Dalsem, Ontario Plants Propagation).COFRA Holding is wholly owned by descendants of its founders, with a multi-generational commitment to stewardship. The COFRA Board of Directors, chaired by Martijn Brenninkmeijer, is responsible for strategic decision-making, supported by a professional management team led by CEO Boudewijn Beerkens. Key individuals like Jens Brenninkmeijer lead Bregal Investments, and Johanna Brenninkmeijer contributes her expertise in impact investments to the board. The firm fosters an environment where professionals can grow and contribute to addressing global challenges.

EMH Partners is a leading growth investment firm based in Munich, Germany, that specializes in partnering with technology businesses and entrepreneurs across Europe, with a particular focus on the German, Austrian, and Swiss (DACH) region. The firm provides strategic capital and deep industry expertise, investing in fast-growing, profitable companies through both minority and majority stakes. EMH Partners aims to build long-term value alongside entrepreneurs and management teams, bridging the gap between traditional venture capital and classic buyout funds by offering growth financing.The firm's origins trace back to 2010 when Maximilian and Sebastian Kuss, after successfully founding and selling their own technology companies, established the EMH Group as private investors. They initially invested over €100 million in young tech and e-commerce companies. In 2016, EMH Partners officially launched its first institutional fund, EMH Growth Fund I, with a hard cap of €350 million. This was followed by EMH Growth Fund II, which closed in 2020 at a hard cap of €650 million, bringing the firm's total committed capital to more than €1.5 billion.EMH Partners boasts a diverse portfolio of technology-driven companies. Notable investments include DIGITEC, a specialist in FX Swaps technology; Snke, a healthtech innovator leveraging AI and big data; Brainlab, which digitizes medical workflows; Occhio, a market leader in high-end design lighting; Native Instruments, a manufacturer of audio production software and hardware; and Stonebranch, a provider of service orchestration and automation solutions. Other portfolio companies span areas like home automation (Basalte), content governance AI (Markup AI, formerly Acrolinx), performance marketing (Smarketer), subscription management (Cleverbridge), and brand experience (Liganova, AVANTGARDE).The team at EMH Partners is characterized by its entrepreneurial heritage and a shared vision for growth. The founders, Maximilian and Sebastian Kuss, bring firsthand experience in building and scaling technology companies. The firm's investment approach is built on integrity, personal relationships, excellence, and an entrepreneurial mindset, supporting partners as both investors and sparring partners. EMH Partners is also committed to sustainability, having become a signatory to the United Nations Principles for Responsible Investment (PRI) in 2020 and a member of the ESG Data Convergence Initiative (EDCI) as of June 2024.

Forbion is a venture capital firm that specializes in the life sciences sector, with a particular focus on biotechnology and pharmaceuticals. Established in 2009, the firm has built a strong reputation for its investments in innovative life sciences companies. Forbion is dedicated to supporting the development of new therapeutics and technologies that can significantly impact healthcare outcomes.The firm operates primarily in Europe and North America, targeting regions that are known for their advancements in life sciences. Forbion's investment strategy emphasizes the importance of fostering innovation in healthcare, and it aims to partner with companies that are at the forefront of scientific research and development.With offices located in Amsterdam, Munich, and San Francisco, Forbion is well-positioned to leverage its extensive network and expertise in the life sciences industry. The firm is recognized for its commitment to nurturing the growth of its portfolio companies, providing not only financial support but also strategic guidance to help them navigate the complexities of the healthcare landscape.

FORUM Family Office is a Munich-based investment firm that has been managing the assets of a single family since 1997. The firm operates with a 100% focus on equity investments, distinguishing itself through a long-term, permanent capital approach. Unlike traditional private equity funds or corporations that often seek quick returns, FORUM Family Office invests for decades, aligning with the generational perspective of family offices. Their investment philosophy is rooted in identifying and nurturing companies with unique business models and competitive advantages, aiming to strengthen them sustainably and secure their succession over generations.The firm's investment strategy is bifurcated into two core competencies: Family Equity and Value Investing. Through Family Equity, FORUM Family Office acquires majority stakes, often 100%, in small and medium-sized privately owned companies, particularly those with recurring revenue models such as subscription businesses. They focus on sectors like software, water & fluid management, and healthcare, with a transaction value typically ranging from €5-50 million. In parallel, their Value Investing arm focuses on listed medium-sized companies in Europe that are market leaders in their respective niches. The insights gained from these public market investments inform and enhance their strategies for Family Equity holdings.FORUM Family Office has a portfolio of 45 companies, employing over 1,700 individuals across six countries. Notable acquisitions include FBS Informatik Holding AG, Siint S.r.l. (through their group company Mecmatica S.r.l.), B+B International S.r.l., and ab-data GmbH & Co KG. The firm prides itself on a decentralized and entrepreneurial approach, fostering trust and aiming for growth that outpaces the market by at least 5% within its holdings.The team at FORUM Family Office comprises professionals across various functions, including analysts, recruiting specialists, and digital marketers, all working towards achieving long-term value for their portfolio companies. The firm has been recognized as a 'Top Company 2025' for its outstanding employee reviews, highlighting its commitment to a valued work environment and team spirit.

Founded in 2000 as Holtzbrinck Ventures and now independent, HV Capital is a venture capital firm headquartered in Munich (with an office in Berlin), supporting European startups at every stage—from early seed rounds to growth financing. Over its nine fund generations, the firm has built a strong track record backing iconic internet and technology disruptors across Europe. HV Capital deploys capital in rounds ranging from €0.5 million at seed level up to €60 million in growth stage investments, with follow‑on reserves up to €100 million per company. Its largest fund to date, Fund IX (closed in May 2023 at approximately €710 million), underscores the firm’s ability to support founders over the long haul. A continuation fund launched in 2022 (HV COCO Growth, €430 million) further demonstrates their commitment to multi‑phase backing. The firm targets sectors including fintech, B2B/SaaS, mobility, consumer marketplaces, healthtech, education and green‑tech. With €2.8 billion in assets under management as of mid‑2023, more than 225 companies backed, and a team of over 60 experienced professionals, HV Capital is one of Europe’s most active and established early‑stage and growth investors.

Kurma Partners is a leading European venture capital firm founded in 2009, headquartered in Paris, France, with an additional office in Munich, Germany. The firm specializes in financing innovation in healthcare, biotechnology, digital health, and related life sciences sectors. Kurma Partners focuses on early-stage and development capital investments, supporting companies that translate disruptive scientific discoveries into cutting-edge medicines and medical devices aimed at treating severe diseases with high unmet medical needs.Kurma Partners has built a strong network of partnerships with top European academic research institutions, hospitals, and industrial experts. This collaborative approach enables the firm to guide portfolio companies from concept through clinical development, providing both equity funding and strategic support. The firm manages dedicated funds such as Kurma Biofund, focused on therapeutics, and Kurma Diagnostics, targeting diagnostics and digital health innovations.With approximately €470 million under management, Kurma Partners has supported over 72 companies and helped create about 25 startups, many of which have become leaders in their respective markets. The firm’s investment strategy spans from seed to growth stages, primarily across Europe, including France, Germany, and broader Southwestern and Southern Europe. Kurma Partners is recognized for its rigorous scientific and business analysis, fostering innovation to improve patient outcomes and address unmet medical needs.

M4Capital is a German family office established in 2015, with a strategic focus on venture capital, private equity, and real estate investments. The firm is headquartered in Munich and Frankfurt am Main, Germany. M4Capital has institutionalized its health tech venture capital activities through its dedicated VC fund, YZR Capital. The firm is driven by a passion for companies that enhance efficiency and transparency, improve quality of life, and facilitate continuous positive change. In its real estate endeavors, M4Capital prioritizes projects that deliver social, environmental, and aesthetic value, adhering to modern ESG criteria.The firm was co-founded by Prof. Dr. Reinhard Meier, who serves as a Managing Partner. Prof. Dr. Meier is a medical doctor, entrepreneur, and investor, known for founding YZR Capital and co-founding TeleClinic, a prominent German healthcare platform that achieved a successful exit to docmorris. Tom Solo also holds a position as Managing Partner, contributing a unique blend of craftsmanship, entrepreneurship, and experience from the media and film industry to the firm's investment strategies.M4Capital's diverse investment portfolio spans various sectors, including health tech, biotechnology, and digital solutions. Notable investments include companies such as Meucci (business/productivity software), 4Ways (healthcare services), Euradia Nuklearmedizin (clinics/outpatient services), Avi Medical, HAIR & SKIN, flair.hr, and Vara. The firm has also achieved successful exits with portfolio companies like Teleclinic, Crashtest Security, and Blikk. M4Capital frequently engages in co-investments, partnering with firms such as Soleria Capital.M4Capital operates with a strong belief in the transformative power of the digital revolution, anticipating rapid industry changes, ongoing disruption of traditional businesses by digital startups, and the increasing dominance of technology companies. The collective expertise of its team, encompassing medical, business, creative, and entrepreneurial backgrounds, underpins M4Capital's strategic approach to identifying and nurturing innovative ventures in a dynamic market landscape.

Munich Re Ventures (MRV) is the corporate venture unit of global reinsurer Munich Re. Since 2014 it has deployed more than $1 billion across early- and growth-stage companies tackling the future of risk—spanning insurtech, climate resilience, industrial IoT, cybersecurity, digital health and new mobility. Headquartered in San Francisco with satellite offices in NYC and Munich, MRV combines financial capital with Munich Re’s underwriting data, client network and 140-year industry know-how. Portfolio highlights include Hippo, At-Bay, Farmer’s Business Network, Snapsheet and Relay. The 30-strong team of investors and operators accelerates product validation, co-development and global scaling for its portfolio, delivering strategic value to both founders and the Munich Re Group.

Possible Ventures is a venture capital firm that invests in mission-driven teams leveraging frontier technologies to address humanity's most significant challenges. The firm focuses on solutions across climate, energy, health, and society, with a strong emphasis on sustainable initiatives, advanced health solutions, and technologies that foster a more equitable future. They are optimistic about technology's potential to drive positive change.Founded in 2013, Possible Ventures was established to back ambitious teams in the early stages of their development. The firm evolved from the Inventures Collective, which aimed to overcome challenges faced by angel investors by harnessing the experience and networks of numerous entrepreneurial angels to support the next generation of founders. Chris Hitchen is identified as the Founder & General Partner, bringing a background as an entrepreneur and investor.Possible Ventures primarily focuses on pre-seed and seed rounds, though they may consider later-stage companies. Their portfolio includes companies such as The Exploration Company, which aims to make space exploration affordable and sustainable; Orbem, which uses AI-powered imaging for better decision-making in agriculture, food, and health; Reverion, focused on decentralized renewable energy; and Marvel Fusion, working on commercially viable nuclear fusion power. Other notable investments include Meatable, developing cultivated meat, and companies in sectors like Electronic Equipment and Instruments, Enterprise Systems (Healthcare), and Metals, Minerals and Mining.The team at Possible Ventures comprises experienced professionals, including Chris Hitchen (Founder & General Partner), Thyra Seitz (Partner), Dr. Christoph Baumeister (Partner), and Tim Linnenweber (Senior Associate). Chris Hitchen has a strong entrepreneurial background, having built and sold several businesses and invested in over 100 startups. Dr. Christoph Baumeister also has co-founded multiple startups. The firm emphasizes a founder-first approach, leveraging their collective experience and a global network of over 200 active investor/entrepreneurs and 250 founders to provide hands-on support and strategic guidance to their portfolio companies.

Reimann Investors is a Munich-based family office and venture capital firm that manages the assets of members of the Reimann entrepreneurial family. The family divested its stake in the former family business in the late 1990s. The firm focuses on long-term investments in both capital markets and corporate direct investments, particularly in young and fast-growing companies.The firm's venture capital arm primarily backs visionary startups with cutting-edge ideas in the B2B Software, Artificial Intelligence (AI), and Fintech sectors. They invest phase-agnostically, typically in Seed and Series A rounds, but also participate in later-stage growth rounds (Series B, C, D). Reimann Investors positions itself as a strategic and active partner, working closely with management to support and promote company development, particularly in the DACH region (Germany, Austria, and Switzerland).Reimann Investors has a portfolio that includes companies in SaaS, FinTech, and Digital Commerce. Notable past investments include SOFORT (now part of Klarna) and XEMPUS. The firm emphasizes providing resources, mentorship, and a network to help startups scale and achieve their potential, focusing on building lasting legacies rather than solely chasing 'unicorns'.The team at Reimann Investors comprises individuals with diverse backgrounds, including engineers, investors, operators, and analysts. Key team members include Hans-Christian Perle and Samuel Schuler as Managing Directors of Reimann Investors Venture Management GmbH, and Isabell Engel as General Counsel. Johannes Poellmann serves as an Investment Manager, supported by Associates and Analysts, bringing a blend of technical knowledge and business expertise to their investment approach.

Somerston Group is a multi-generation single-family office with a diversified investment portfolio spanning both private and listed markets. The firm's investment strategy encompasses a broad range of asset classes, from real estate to software. They actively engage in real estate development and investment, focusing on areas such as community master planning, healthcare and social infrastructure, hotels and leisure, land development, retail, and pioneering data center and telecommunications real estate. Additionally, Somerston Group manages innovation-focused funds that target early-stage and pre-IPO technology companies, and through Somerston Asset Management, they operate various listed liquid asset portfolios.The origins of the Somerston Group trace back to the 1850s, when the founding family was involved in the shipping industry. Over a century later, in the late 1960s and 1970s, the family strategically shifted its focus, pivoting towards property development as its primary area of investment. While the family office's roots are deep, the Somerston Group as a formal investment entity has evolved to manage these diverse holdings and also collaborates with other families who share its investment ethos.Somerston Group's notable investments include companies like Shield AI in the aerospace and defense sector, and Ubicquia and CoreWeave within the business and productivity software industries. The firm was a pioneer in data center and telecommunications real estate development, notably contributing its data center assets to Digital Realty Trust's IPO in 2004. In real estate, they are the master developer of large-scale projects such as River Islands in California and have developed numerous shopping centers across Europe through their subsidiary, Newbridge. The firm has also seen successful exits, including BETA Technologies and Somerston Hotels, which was acquired and rebranded as Atlas Hotels.The firm operates with a decentralized management structure, emphasizing the empowerment of strong local management teams to execute investment projects. Key individuals within the Somerston Group include Bill Scott, who serves as the US CFO for The Cambay Group, bringing extensive experience in real estate development. Aaron Knapik is the Managing Director for Somerston's Venture Capital and Private Equity portfolio, while Nick Wakefield is the CIO for Somerston Treasury and Managing Director of Somerston Asset Management. The team's collective expertise spans investment, development, finance, and asset management across various sectors and geographies, supported by a board with deep legal and financial acumen.

Ventura Biomed Investors is a venture capital firm based in Munich, Germany, dedicated to shaping the future of biomedicine by investing in early-stage life science companies. The firm focuses on pioneering technologies and innovative therapies within the European market. They typically invest between EUR 1 and 5 million per company, often in consortia with other funds. To broaden their impact, Ventura Biomed Investors also leverages its investment platform, Ventura Ace, which includes a network of selected private investors.The firm was founded by Dr. Andreas Jenne and Dr. Kurt Rudolf Schwarz, both serial entrepreneurs with extensive experience in the biotech and pharmaceutical industries. Dr. Jenne has a strong background in launching and managing biotech companies, including Kinaxo and NEO New Oncology, both of which were successfully acquired. Dr. Schwarz is an active investor and business angel with affiliations including Merck & Co., Harvard Medical School, and Massachusetts General Hospital, and previously served on the supervisory board of Schwarz Pharma.Ventura Biomed Investors boasts a diverse portfolio of innovative life science companies. Notable investments include Kupando, which develops TLR 4/7 agonists for oncology and infectious diseases; NEOSPHERE Biotechnologies, a proteomics company focused on discovering therapeutic degrader targets; IRUBIS, offering real-time bioprocess monitoring instruments; Abalos Therapeutics, developing a novel virus-based anti-cancer therapy; and Navignostics, providing spatial single-cell proteomic analysis for personalized cancer treatment. The firm's investments span areas such as drug discovery, diagnostics, and bioprocess technology.The leadership team's deep industry knowledge and broad investor and business network are crucial to their strategy. They actively support the long-term development of their portfolio companies, providing not just capital but also strategic guidance and access to key industry connections. This hands-on approach aims to accelerate medical breakthroughs and address unmet patient needs.